Display options
Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;37(12):110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 37(12), 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. 37,12 (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942; PMCID: PMC8639452.
Copy Download .nbib Format: NLM
Share it on

Cell Rep. 2021 Dec 21;37(12):110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yang Yu, Na Xu, Qi Cheng, Fei Deng, Meiqin Liu, Airu Zhu, Yuan-Qin Min, Dan Zhu, Wenbo Huang, Xu Feng, Xizhong Jing, Ying Chen, Daoyuan Yue, Yawei Fan, Chang Shu, Qing Guan, Zifeng Yang, Jincun Zhao, Wenjun Song, Deyin Guo, Huanliang Liu, Jindong Zhao, Ping Lan, Zhengli Shi, Yingfang Liu, Xiaoping Chen, Huanhuan Liang

Affiliations

  1. School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
  2. School of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
  3. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China.
  4. State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan, Hubei 430071, China.
  5. CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan 430071, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  6. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
  7. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, NHFPC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research. Beijing 100191, China.
  8. Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  9. State Key Laboratory of Respiratory Disease, Institute of Integration of Traditional and Western Medicine, Guangzhou Medical University, Guangzhou, Guangdong 510180, China.
  10. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China; Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
  11. State Key Laboratory of Protein and Plant Genetic Engineering, College of Life Sciences, Peking University, Beijing 100871, China.
  12. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China. Electronic address: [email protected].
  13. CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan 430071, China. Electronic address: [email protected].
  14. School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China. Electronic address: [email protected].
  15. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China; Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China. Electronic address: [email protected].
  16. School of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong 518107, China. Electronic address: [email protected].

PMID: 34910942 PMCID: PMC8639452 DOI: 10.1016/j.celrep.2021.110126

Abstract

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key factors participating in the cytokine storm. Here we demonstrate that interferon-induced protein 35 (IFP35) plays an important role in the cytokine storm induced by SARS-CoV-2 and influenza virus infection. We find that the levels of serum IFP35 in individuals with SARS-CoV-2 correlates with severity of the syndrome. Using mouse model and cell assays, we show that IFP35 is released by lung epithelial cells and macrophages after SARS-CoV-2 or influenza virus infection. In addition, we show that administration of neutralizing antibodies against IFP35 considerably reduces lung injury and, thus, the mortality rate of mice exposed to viral infection. Our findings suggest that IFP35 serves as a biomarker and as a therapeutic target in virus-induced syndromes.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: COVID-19; IFP35; biomarker and therapeutic target; cytokine storm; influenza virus

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Publication Types